conf 2/10 partial
enthusiasm:18.0 · trend:8 · quantifies:0 · impact:0 · under_radar:14 · credibility:0 · business_impact:8 · disruption:0 · commitment:6 · confirmation:3
Enthusiasm latest 6 / prev 3 (rising)
BMY's AI thesis is centered on R&D productivity, not commercial demand: faster molecule identification, streamlined clinical operations, shorter development timelines, and quality oversight. Credibility improved in Q1 FY2026 because management tied AI to specific R&D workflow areas and quantified productivity targets, though they did not tie AI directly to revenue, margins, headcount, or dollar cost savings.
Grounded on actual base — revenue $48.2B · net income $7.1B · net margin 14.6% · diluted EPS 3.45
These are next-fiscal-year annual uplift estimates, not next-quarter numbers.
Aggregate next-FY est. rev uplift: % · next-FY EPS uplift: % · vs analysts: unclear · priced in: low (model's call-read: medium; verdict above is the hard-data one used for ranking) · confidence: 2/10
| Claim | Figure | Arithmetic | Next-FY Rev % | Next-FY EPS % |
|---|---|---|---|---|
| Lead molecule ID ~50% faster productivity · soft | ~50% faster (lead molecule identification) | Process-speed metric in early discovery. No $ saving, no R&D-spend base disclosed, no timeframe. Cannot map 'X% faster on a research step' to incr_rev / $48.194B revenue or after-tax saving / $7.053B NI without inventing an R&D base and attribution rate. Per guardrail, no number invented. | ||
| 30% reduction in development cycle times productivity · soft | 30% reduction in cycle times (over time, vs a few years ago) | Efficiency metric with no dollar anchor and explicitly long-dated ('over time'). Faster cycles could lower dev cost or pull revenue forward, but no $ on the affected cost line and no next-FY phasing given. after_tax_saving = saving_$ x (1-0.21) is uncomputable with saving_$ unknown. No number invented. |
Assumptions: Tax rate 21% and incremental net margin = current 14.6% would be the defaults IF a dollar figure existed, but neither claim supplies a $ base (R&D spend, opex saving, or incremental revenue), so no arithmetic is possible. Phasing N/A — both claims are explicitly long-dated ('over time', 'versus a few years ago') with no next-FY portion. Both map to the R&D/discovery process, not to a sized revenue or cost line.
Top line: No sizable topline impact can be computed. Both AI claims are R&D-process speed/efficiency metrics (50% faster lead ID; 30% shorter cycles) with no dollar anchor. Faster discovery may improve long-run pipeline odds but does not translate to a quantifiable FY26 revenue line off the $48.2B base.
Bottom line: No quantifiable EPS uplift. The claims are productivity gains without a disclosed opex-saving figure, so after_tax_saving and eps_uplift_pct are uncomputable against the $7.05B net income base. Management frames AI under its existing cost-savings initiative ('delivered on our cost savings initiative in 2025'), implying any benefit is folded into already-guided savings rather than incremental.
[impact n/m (all claims soft/unanchored)] Nothing to add to consensus numerically — both claims are null/soft. Consensus already embeds the cost program: forward EPS sits well above reported diluted EPS of 3.45 (FY26E ~6.32) and net income ~$13.0B vs $7.05B actual, while revenue is flat-to-declining (~$47.28B FY26 vs $48.194B current, -1.89%). Management explicitly ties AI to the cost-savings initiative it already 'delivered' in 2025, so the efficiency upside is most likely captured in the existing margin/EPS uplift analysts already model — not a fresh catalyst. With no computable next-FY dollar impact, there is no arithmetic basis to claim it is ahead of consensus.
partial
Both agree all figures null, adopter-side, productivity, priced_in medium. Only confidence differed; took lower. Merged Y's stronger evidence on long-dated framing and cost-savings folding.
| Field | Opus 4.8 | GPT-5.5 |
|---|---|---|
| Rev uplift % | – | – |
| EPS uplift % | – | – |
| Priced in | medium | medium |
| vs analysts | unclear | unclear |
| Confidence | 2 | 3 |
| Top line | No sizable topline impact can be computed. Both AI claims are R&D-process speed/efficiency metrics (50% faster lead ID; 30% shorter cycles) with no dollar anchor. Faster discovery may improve long-run pipeline odds but does not translate to a quantifiable FY26 revenue line off the $48.2B base. | No calculable next-FY revenue uplift: both AI claims are adopter-side productivity/cycle-time claims without a disclosed revenue dollar bridge, so rev uplift versus $48.194B current revenue is null. |
| Bottom line | No quantifiable EPS uplift. The claims are productivity gains without a disclosed opex-saving figure, so after_tax_saving and eps_uplift_pct are uncomputable against the $7.05B net income base. Management frames AI under its existing cost-savings initiative ('delivered on our cost savings initiative in 2025'), implying any benefit is folded into already-guided savings rather than incremental. | No calculable EPS uplift: faster lead ID and 30% shorter development cycles may improve R&D productivity, but no saving amount or affected cost base is disclosed, so uplift versus $7.053B current net income is null. |
| Reasoning | Nothing to add to consensus numerically — both claims are null/soft. Consensus already embeds the cost program: forward EPS sits at ~6.11 (FY25E) / 6.32 (FY26E) vs reported diluted EPS of 3.45, and net income ~$12.7-13.1B vs $7.05B actual, while revenue is flat-to-declining (47.99B -> 47.28B -> 46.28B). Management explicitly ties AI to the cost-savings initiative it already 'delivered' in 2025, so the efficiency upside is most likely captured in the existing margin/EPS uplift analysts already model — not a fresh catalyst above the line. | Consensus 2026 revenue is $47.282B, down $0.912B vs current $48.194B, or -1.89%. Consensus 2026 EPS is $6.31668 vs current $3.45, up 83.09%; consensus 2026 net income is $13.056B vs current $7.053B, up 85.10%. Because the AI claims have no computable next-FY dollar impact, there is no arithmetic basis to say they are ahead of consensus. |
Rows highlighted where the two models disagreed.
—/100 (no quantified promises) too-early 6 calls reviewed
BMS made no judgeable quantified AI commitments until Q1 FY2026, when it set R&D productivity targets (~50% faster lead-molecule ID, ~30% cycle-time reduction) tied to AI and automation. Because these promises are new with no later results in the set, AI delivery credibility cannot yet be scored.
Est. revisions flat · Fwd P/E 8.9 · EV/Sales 3.0x
AI claim maps to Other Growth Brands, Opdivo, Cobenfy
AI enthusiasm across 6 calls — trend ↗ rising
AI moved from absent to broad efficiency rhetoric, then became a specific R&D productivity lever with targets and partnerships.
7/10 qualitative impact material medium-term · mixed evidence
Where AI matters: R&D discovery and clinical development productivity
BMY is applying AI to core pharma R&D workflows, with specific targets for roughly 50% faster lead molecule identification and 30% shorter development cycle times. That can materially improve pipeline productivity and cost efficiency, but the claims are not tied to revenue, EPS, or proven launch outcomes yet.
Caveats: AI targets are newly announced and not yet proven; No disclosed dollar savings or revenue attribution; R&D speed gains may not translate into successful approvals; Competitors can use similar AI tools
AI DISRUPTION / CANNIBALIZATION RISK tailwind · 1/10
AI does not commoditize BMY's core business of patented drugs, clinical evidence, regulatory approvals, and commercial scale. If anything, broader AI access may raise discovery competition, but it does not directly deflate the value of approved therapeutics.
option liquidity: good
proxy inputs — dollar-ADV $630M · beta 0.259 · px $54.46
source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.